Results 261 to 270 of about 361,630 (339)

Long‐term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb‐threatening ischaemia

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Data about long‐term clinical outcomes of revascularization procedures, especially for autologous cell therapy (ACT), in diabetic patients with chronic limb‐threatening ischaemia (CLTI) are lacking. The aim of our study was to compare the mortality and amputation rates in patients with diabetic foot ulcers (DFU) and CLTI treated by ACT ...
M. Dubský   +8 more
wiley   +1 more source

GLYCATED HEMOGLOBIN (HbA1c)

open access: bronze, 2015
Saeed Akram Bhatti   +2 more
openalex   +2 more sources

Association of time in tight range and 1,5‐anhydroglucitol in type 2 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Among the novel metrics derived from continuous glucose monitoring (CGM), time in tight range (TITR) has gained increasing attention. Our study aimed to investigate the relationship between 1,5‐anhydroglucitol (1,5‐AG) and TITR in patients with type 2 diabetes.
Hang Su   +9 more
wiley   +1 more source

Risk factors for development of diabetic foot ulcer disease in two large contemporary UK cohorts

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Diabetic foot ulcer disease (DFUD) is common, life‐changing and associated with a lower 5‐Year survival rate than many cancers. However, the risk factors for DFUD have generally been identified in small, single‐centre, clinic‐based studies, many of which are cross‐sectional.
Safoora Gharibzadeh   +20 more
wiley   +1 more source

Long‐term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real‐world setting in Finnish paediatric and adult individuals with type 1 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The use of automated insulin delivery (AID) systems is associated with improved glycaemic control in individuals with type 1 diabetes (T1DM). However, AID systems are more expensive than other treatment modalities for T1DM. The aim of this study was to evaluate the long‐term cost‐effectiveness of AID compared to continuous subcutaneous ...
Heta‐Leena Vallivaara   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy